Newsroom

LONDON, April 22, 2025 /PRNewswire/ – MYndspan, the first company to offer clinical-grade MEG brain scanning to consumers, today announced an exclusive partnership with IMEDCO, the global leader in magnetically shielded room (MSR) infrastructure. IMEDCO will be the sole supplier of MSRs for all future MYndspan scanning sites.

LONDON, April 14, 2025 /PRNewswire/ – MYndspan, the first company to offer clinical-grade MEG brain scanning to consumers, today announced the appointment of Nawal Roy, Founder and CEO of Holmusk, as a strategic advisor. Roy’s expertise in behavioral health data science and real-world evidence will help accelerate MYndspan’s mission to make measurable brain health accessible to all.

LONDON, April 10, 2025 /PRNewswire/ – MYndspan, the first company to offer clinical-grade MEG brain scanning to consumers, today announced a strategic investment from EMOTIV, a global leader in neurotechnology and wearable EEG. EMOTIV joins as a key backer in MYndspan’s crowd funding campaign, which launched today.

LONDON, April 8, 2025 /PRNewswire/ – MYndspan, the first company to bring clinical-grade Magnetoencephalography (MEG) brain scanning directly to consumers, has launched its equity crowdfunding campaign on Crowdcube. Backed by strategic partnerships with neurotech leaders MEGIN, IMEDCO, Bios Health and Re:Cognition Health, MYndspan is unlocking access to the most advanced, non-invasive measure of brain function, starting at its flagship London centre.

LONDON, Feb. 27, 2025 /PRNewswire/ – MYndspan, a pioneer in consumer brain health technology, announced a new partnership today with MEGIN, the global leader in magnetoencephalography (MEG), to make high-precision brain scanning more widely available. This collaboration will allow MYndspan to introduce consumer-accessible MEG brain scans, beginning with its flagship location in London later this year.

LONDON, Feb. 3, 2025 /PRNewswire/ – MYndspan, a pioneer in consumer brain health technology, and BIOS Health, a leader in real-time neural data analysis and dosing, today announced a partnership to scale the reach and impact of precision neuroscience. By combining MYndspan’s Magnetoencephalography (MEG) powered brain scans with BIOS Health’s proprietary neural data and AI platform, the companies are making advanced neural insights and interventions more widely accessible.

LONDON, June 12, 2024 /PRNewswire/ – MYndspan, a brain health technology company, announced today a new study published in Imaging Neuroscience. “Predicting brain age across the adult lifespan with spontaneous oscillations and functional coupling in resting brain networks captured with magnetoencephalography” used MYndspan’s analysis to predict how healthy brains age. With data captured from Magnetoencephalography (MEG), a non-invasive functional brain imaging technology, researchers modelled the trajectories of healthy brain ageing throughout the adult lifespan, identifying markers of accelerated brain ageing brought on by injury or disease.

LONDON, UK, May 21, 2024 /PRNewswire/ – MYndspan, a brain health technology company, announced today the opening of its first brain health centre in Birmingham, UK. With neurological conditions now the leading cause of poor health worldwide, MYndspan is on a mission to improve access to preventive and proactive brain health technology. With today’s announcement, MYndspan becomes the first company in the world to bring non-invasive Magnetoencephalography (MEG) directly to consumers interested in learning more about their brains. MEG is the most advanced method of recording and evaluating the brain while it is actively functioning but has typically been accessible only in research and clinical trial settings.